| Basics |
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.
|
| IPO Date: |
June 1, 1998 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$170.63M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 2.84%
|
| Avg Daily Range (30 D): |
$0.07 | 3.56%
|
| Avg Daily Range (90 D): |
$0.05 | 3.04%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.44M |
| Avg Daily Volume (30 D): |
.89M |
| Avg Daily Volume (90 D): |
.71M |
| Trade Size |
| Avg Trade Size (Sh.): |
335 |
| Avg Trade Size (Sh.) (30 D): |
264 |
| Avg Trade Size (Sh.) (90 D): |
227 |
| Institutional Trades |
| Total Inst.Trades: |
279 |
| Avg Inst. Trade: |
$1.62M |
| Avg Inst. Trade (30 D): |
$.58M |
| Avg Inst. Trade (90 D): |
$2.98M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$5M |
| Avg Closing Trade (30 D): |
$.58M |
| Avg Closing Trade (90 D): |
$3.89M |
| Avg Closing Volume: |
628.06K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$.05
|
$-.05
|
$.09
|
|
Diluted EPS
|
$.04
|
$-.05
|
$.09
|
|
Revenue
|
$ 59.76M
|
$ 10.11M
|
$ 18.22M
|
|
Gross Profit
|
$ 29.87M
|
$ 1.93M
|
$ 14.33M
|
|
Net Income / Loss
|
$ 3.91M
|
$ -3.62M
|
$ 6.49M
|
|
Operating Income / Loss
|
$ 4.63M
|
$ -4.15M
|
$ 7.21M
|
|
Cost of Revenue
|
$ 29.9M
|
$ 8.18M
|
$ 3.89M
|
|
Net Cash Flow
|
$ -4.19M
|
$ -.29M
|
$ -7.7M
|
|
PE Ratio
|
56.75
|
|
|
| Splits |
|
Dec 20, 2019:
1:10
|
|
Jan 03, 2007:
1:10
|
|
|
|
